In the latest quarter, 15 analysts provided ratings for BioNTech BNTX, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

While the best companies are hard to find, but they can generate massive returns over long periods. To wit, the BioNTech SE ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

The pharma’s lawsuit focuses on scientific work that helped clear the path for creating mRNA vaccines to fight the COVID-19 ...

BioNTech has a broad and diversified cancer drug pipeline extending well beyond mRNA based approaches. Sam Fazeli, Senior Health Care Analyst, speaks to Ryan Richardson, Chief Strategy Officer, who ...

Pfizer and BioNTech had filed their lawsuit in September 2022 over patents relating to messenger RNA (mRNA) technology, which underpins Pfizer and BioNTech's COVID-19 vaccine.

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $145.00. The company’s shares closed last ...

We recently published a list of 8 High Growth UK Stocks to Invest In. In this article, we are going to take a look at where ...

Its chief digital and technology officer Lidia Fonseca offered a fascinating insight into how one biggest ... the pandemic (alongside the likes of BioNTech, Moderna and AstraZeneca) – has ...

Dates for 2025 will be confirmed once applications open in January 2025. For most courses, completing Insight into Bristol guarantees participants a contextual offer, providing they meet the full ...

DUBLIN--(BUSINESS WIRE)--The "CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027" report has ... companies and biotech firms, including BioNTech, Genmab, Adagene, and Shanghai ...

Jonathan Coachman thinks Pat McAfee is a unicorn in the world of commentary. The Coach recently appeared on Insight with ...